Home > Research > Publications & Outputs > Amyloid β-peptide and Alzheimer's disease
View graph of relations

Amyloid β-peptide and Alzheimer's disease

Research output: Contribution to Journal/MagazineLiterature reviewpeer-review

Published

Standard

Amyloid β-peptide and Alzheimer's disease. / Allsop, David; Mayes, Jennifer.
In: Essays in Biochemistry, Vol. 56, 7, 18.08.2014, p. 99-110.

Research output: Contribution to Journal/MagazineLiterature reviewpeer-review

Harvard

Allsop, D & Mayes, J 2014, 'Amyloid β-peptide and Alzheimer's disease', Essays in Biochemistry, vol. 56, 7, pp. 99-110. https://doi.org/10.1042/bse0560099

APA

Allsop, D., & Mayes, J. (2014). Amyloid β-peptide and Alzheimer's disease. Essays in Biochemistry, 56, 99-110. Article 7. https://doi.org/10.1042/bse0560099

Vancouver

Allsop D, Mayes J. Amyloid β-peptide and Alzheimer's disease. Essays in Biochemistry. 2014 Aug 18;56:99-110. 7. doi: 10.1042/bse0560099

Author

Allsop, David ; Mayes, Jennifer. / Amyloid β-peptide and Alzheimer's disease. In: Essays in Biochemistry. 2014 ; Vol. 56. pp. 99-110.

Bibtex

@article{7eab2c0912ac434da08adc7e69c555ec,
title = "Amyloid β-peptide and Alzheimer's disease",
abstract = "One of the hallmarks of Alzheimer{\textquoteright}s disease (AD) is the formation of senile plaques in the brain, which contain fibrils composed of the amyloid-β (Aβ) peptide. According to the {\textquoteleft}amyloid cascade{\textquoteright} hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of Aβ and towards smaller and more soluble {\textquoteleft}oligomers{\textquoteright} as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation Aβ from the amyloid precursor protein (APP), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral Aβ, which are still the main hope for providing a more effective treatment for AD in the future.",
keywords = "amyloid cascade , genetics, oligomer, secretase, senile plaque, treatment",
author = "David Allsop and Jennifer Mayes",
year = "2014",
month = aug,
day = "18",
doi = "10.1042/bse0560099",
language = "English",
volume = "56",
pages = "99--110",
journal = "Essays in Biochemistry",
issn = "0071-1365",
publisher = "Portland Press Ltd.",

}

RIS

TY - JOUR

T1 - Amyloid β-peptide and Alzheimer's disease

AU - Allsop, David

AU - Mayes, Jennifer

PY - 2014/8/18

Y1 - 2014/8/18

N2 - One of the hallmarks of Alzheimer’s disease (AD) is the formation of senile plaques in the brain, which contain fibrils composed of the amyloid-β (Aβ) peptide. According to the ‘amyloid cascade’ hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of Aβ and towards smaller and more soluble ‘oligomers’ as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation Aβ from the amyloid precursor protein (APP), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral Aβ, which are still the main hope for providing a more effective treatment for AD in the future.

AB - One of the hallmarks of Alzheimer’s disease (AD) is the formation of senile plaques in the brain, which contain fibrils composed of the amyloid-β (Aβ) peptide. According to the ‘amyloid cascade’ hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of Aβ and towards smaller and more soluble ‘oligomers’ as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation Aβ from the amyloid precursor protein (APP), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral Aβ, which are still the main hope for providing a more effective treatment for AD in the future.

KW - amyloid cascade

KW - genetics

KW - oligomer

KW - secretase

KW - senile plaque

KW - treatment

U2 - 10.1042/bse0560099

DO - 10.1042/bse0560099

M3 - Literature review

VL - 56

SP - 99

EP - 110

JO - Essays in Biochemistry

JF - Essays in Biochemistry

SN - 0071-1365

M1 - 7

ER -